`
`Lupin Pharmaceuticals, Inc.
`
`Newsroom
`
`Lupin Receives Tentative Approval for Generic Prezista~®
`Tablets
`
`Mumbai, Baltimore, December 30, 2014: Pharma Major Lupin
`Limited (Lupin) announced today that it has received tentative
`approval for its Darunavir Ethanolate Tablets 75 mg, 150 mg, 300
`mg, 400 mg, 600 mg and 800 mg from the United States Food and
`Drugs Administration (FDA) to market a generic version of Janssen
`Products, LP (Janssen) Prezista/3,® Tablets 75 mg, 150 mg, 300 mg,
`400 mg, 600 mg.
`Lupin’s Darunavir Ethanolate Tablets 75 rag, 150 mg, 300 rag, 400
`mg, 600 mg are the AB-rated generic equivalents of Janssen~(cid:128)TMs
`Prezista/~® tablets and are indicated Lupin~(cid:128)TMS Darunavir Tablets is
`indicated for the treatment of HIV-1 infections.
`Prezista~.® Tablets had annual U.S sales of US$ 1.2 billion (IMS MAT
`September, 2014).
`
`About Lupin Limited
`Lupin is an innovation led transnational pharmaceutical company
`producing and developing a wide range of branded and generic
`formulations as well as biotechnology products and APIs globally. The
`Company is a significant player in the Cardiovascular, Diabetology,
`Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds
`global leadership positions in the Anti-TB and Cephalosporin segment.
`
`Lupin is the 5th largest and fastest growing top 5 generics player in
`the US (5.3% market share by prescriptions, IIVIS Health) and the 3rd
`largest Indian pharmaceutical company by sales. The Company is also
`amongst the top 10 generic pharmaceutical players in Japan and
`South Africa (IMS). For the financial year ended March 2014, Lupin’s
`Consolidated turnover and Profit after Tax were Rs. 110,866 million
`(USD 1.83 billion) and Rs. 18,364 million (USD 304 million)
`respectively. Please visit http://www.lupin.com for more information.
`
`(:IN: L24100MH1983PLC029442 Registered Office: 159, C.S.T.
`Road, Kalina, Santacruz (East), Mumbai - 400 098.
`
`About Lupin Pharmaceuticals Inc.
`Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is
`dedicated to delivering high-quality, affordable generic medicines and
`branded formulations trusted by healthcare professionals and patients
`across geographies. For more information, please do visit
`http://www.lu pin ph armaceuticals.com
`You could also follow us on Twitter - www.twitter.com/lupinlimited
`
`For more information, please contact - Shamsher Gorawara
`Head - Corporate Communications
`Ph: +91- 98 20 338 555
`Email: shamshergorawara@lu pinpharma.com
`
`http://www.lupinpharm aceuticals.com/30dec2014.htm
`
`Lupin Ex. 1068 (Page 1 of 2)
`
`
`
`4/8/2015
`
`Lupin Pharmaceuticals, Inc.
`
`Or
`
`Alpesh Dalai
`Head - M & A and Investor Relations
`Lupin Limited
`Ph: +91 98 20 023 511
`Emaih alpeshdalal@ lu pin pharma,¢om
`
`Safe Harbor Statement *
`Prezista/~® is a registered
`Pharmaceuticals.
`
`trademark of Tibotec
`
`http://www.lupinphar maceuticals.com/30dec2014.htm
`
`Lupin Ex. 1068 (Page 2 of 2)
`
`2/2
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
